Skip to main content

Kalaris Therapeutics, Inc.

corporate_fare Company Profile

Kalaris Therapeutics, Inc.

KLRS·NASDAQ·Life Sciences·CIK 0001754068

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing treatments for prevalent retinal diseases with significant unmet medical needs. The company is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug. TH103 is engineered for extended intraocular retention and enhanced VEGF inhibition in patients with exudative and/or neovascular retinal diseases. It is a fully humanized recombinant fusion protein that functions as a "decoy receptor" (a VEGF trap), utilizing molecular properties of the human body's native, highest affinity VEGF receptor 1. Preclinical studies comparing TH103 to aflibercept, a current market-leading anti-VEGF agent, demonstrated more anti-VEGF activity and longer duration of activity for TH103. In December 2025, initial data from the Phase 1a single ascending dose (SAD) trial of TH103 in treatment-naïve neovascular Age-related Macular Degeneration (nAMD) patients showed TH103 was generally well tolerated and improved functional and anatomical outcomes at 1-month post-dosing. Preliminary single dose pharmacokinetic data from this trial suggest TH103 may offer extended treatment durability after a standard four-dose loading regimen. Kalaris Therapeutics, Inc. is investigating TH103 for nAMD, a leading cause of blindness in the United States and Europe, affecting an estimated 1.6 million adults in the United States. The global branded market for prevalent exudative and/or neovascular retinal diseases was an estimated $15 billion in 2024.

Kalaris Therapeutics, Inc. (NASDAQ:KLRS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for KLRS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for KLRS spans 10-Q, 8-K, 424B3, S-3.

Recent high-impact activity:

  • Kalaris 10-Q: Material Weaknesses Persist, TH103 Phase 1b/2 Data Slipped to 2H 2027
  • Kalaris Extends Cash Runway Into 2028, But TH103 Data Slips to 2H 2027
  • Kalaris Posts $11.5M Q2 Loss, Cash Runway Into Q4 2027; Phase 1b/2 Data Due 1H 2027
  • Kalaris Unveils Expanded Phase 1a Data for TH103 in nAMD, Highlighting Durable Responses and a Clean Safety Profile at the 2.5 mg Dose
  • TH103 Shows Durable Responses in Expanded AMD Trial, 29% Treatment-Free at 6 Months

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$43.44M
Diluted EPS
-$2.85
Op. Cash Flow
-$38.37M
Operating Income
-$46.15M
Cash & Equivalents
$98.05M
Debt / Equity
0.00×
Shares Outstanding
22.9M sh
Source: 10-K · filed 2026-03-17 · accession 0001193125-26-110659

Short Interest & Short Volume

5.43 days to cover

FINRA reported short interest of 366,632 shares in KLRS as of the October 30, 2026 settlement, a 19.7% increase from the prior period — about 5.4 days to cover at its recent average daily volume. On November 19, 2026, 27.4% of KLRS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)366,632 shares as of October 30, 2026
Change vs prior period▲ 19.7%
Days to cover5.43 at avg daily volume of 67,573
Daily short volume (FINRA facilities)27.4% of 6,257 shares on November 19, 2026
5-day average short volume28.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$1.28 -5.19% today
52-week range · as of 2026-11-10 $1.28 – $11.88
Market cap
$27.96M
Volume
38K (0.5× avg)
3-mo avg 83.6K
Live data · 2026-11-20 21:19 UTC · After hours

show_chartPrice Chart

Loading chart...

feed KLRS - Latest Insights

KLRS
Nov 10, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.85
Real-time Price: $1.28 info
Change: -$0.570 (-31%) info
Market Cap: $27.955M info
KLRS
Nov 10, 2026, 7:30 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.30
Real-time Price: $1.28 info
Change: -$1.02 (-44%) info
Market Cap: $27.955M info
KLRS
Aug 11, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.27
Real-time Price: $1.28 info
Change: -$2.99 (-70%) info
Market Cap: $27.955M info
KLRS
Jul 17, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.66
Real-time Price: $1.28 info
Change: -$3.38 (-73%) info
Market Cap: $27.955M info
KLRS
Jul 17, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.58
Real-time Price: $1.28 info
Change: -$3.30 (-72%) info
Market Cap: $27.955M info
KLRS
Jun 23, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.40
Real-time Price: $1.28 info
Change: -$3.12 (-71%) info
Market Cap: $27.955M info
KLRS
May 12, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.79
Real-time Price: $1.28 info
Change: -$3.51 (-73%) info
Market Cap: $27.955M info
KLRS
May 12, 2026, 8:08 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.82
Real-time Price: $1.28 info
Change: -$3.54 (-73%) info
Market Cap: $27.955M info
KLRS
Apr 13, 2026, 4:19 PM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $6.31
Real-time Price: $1.28 info
Change: -$5.03 (-80%) info
Market Cap: $27.955M info
KLRS
Apr 13, 2026, 4:18 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $6.31
Real-time Price: $1.28 info
Change: -$5.03 (-80%) info
Market Cap: $27.955M info
KLRS
Apr 10, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.30
Real-time Price: $1.28 info
Change: -$5.02 (-80%) info
Market Cap: $27.955M info
KLRS
Apr 03, 2026, 4:19 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $5.79
Real-time Price: $1.28 info
Change: -$4.51 (-78%) info
Market Cap: $27.955M info
KLRS
Apr 03, 2026, 4:11 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $5.79
Real-time Price: $1.28 info
Change: -$4.51 (-78%) info
Market Cap: $27.955M info
KLRS
Mar 17, 2026, 4:00 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $8.52
Real-time Price: $1.28 info
Change: -$7.24 (-85%) info
Market Cap: $27.955M info
KLRS
Mar 17, 2026, 8:08 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.81
Real-time Price: $1.28 info
Change: -$7.53 (-85%) info
Market Cap: $27.955M info
KLRS
Mar 09, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.82
Real-time Price: $1.28 info
Change: -$8.54 (-87%) info
Market Cap: $27.955M info
KLRS
Feb 17, 2026, 8:15 PM EST
Filing Type: 4
Importance Score:
9
Price at Filing: $8.27
Real-time Price: $1.28 info
Change: -$6.99 (-85%) info
Market Cap: $27.955M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets